SXSW 2025
The Future of PTSD Treatment: With or Without MDMA
Description:
In today’s mental health crisis, nearly 1 in 10 Americans will suffer from PTSD—it’s an uncertain time for veterans and others suffering given the FDA’s resistance to MDMA legalization. However, MDMA is not the only wonder drug or treatment for PTSD. The psychedelic therapy paradigm, supporting people to get to the root of trauma, is a common thread with different modalities and protocols, each with unique approaches and outcomes. From MDMA, ketamine, and ibogaine to integration therapy, experts share everything you need to know about these groundbreaking options saving lives today.
Related Media
Other Resources / Information
Takeaways
- Ketamine Today, MDMA Tomorrow: Compare and Contrast these Therapies, and a Landmark Study offers New Hope
- Unlocking Hidden Paths to Healing: How Ibogaine Offers Unexpected Relief for PTSD Sufferers
- A “Theradelic” Approach: How EMDR, Psychedelic Therapy, and other Unique Modalities Can Heal PTSD
Speakers
- Dr. Steven Radowitz, Co-Founder, Chief Medical Officer, Nushama
- Casey Paleos, MD, Founder, Nautilus Sanctuary
- Sunny Strasburg, LMFT, Founder, The Theradelic Approach
- Talia Eisenberg, Co-Founder, Beond
Organizer
Marissa Feinberg, Founder, Psychedelics for Climate Action (PSYCA)
SXSW reserves the right to restrict access to or availability of comments related to PanelPicker proposals that it considers objectionable.
Add Comments